PNC Financial Services Group Inc. Buys 499 Shares of Agios Pharmaceuticals, Inc. $AGIO

PNC Financial Services Group Inc. increased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 16.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,582 shares of the biopharmaceutical company’s stock after buying an additional 499 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Agios Pharmaceuticals were worth $105,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of AGIO. GF Fund Management CO. LTD. bought a new stake in Agios Pharmaceuticals during the fourth quarter worth $39,000. CWM LLC grew its holdings in Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 996 shares in the last quarter. Sterling Capital Management LLC grew its holdings in Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 1,587 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in Agios Pharmaceuticals by 7.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company’s stock worth $194,000 after buying an additional 394 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in Agios Pharmaceuticals by 9,296.6% during the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 8,088 shares in the last quarter.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 11,914 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the transaction, the insider owned 61,271 shares in the company, valued at $2,327,685.29. This trade represents a 16.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Cecilia Jones sold 1,780 shares of the firm’s stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $59,701.20. Following the completion of the transaction, the chief financial officer owned 30,049 shares of the company’s stock, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,448 shares of company stock worth $2,026,141 in the last three months. Corporate insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $36.22 on Wednesday. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of 3.29 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock has a fifty day moving average of $36.61 and a 200-day moving average of $32.80.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Wall Street Analyst Weigh In

AGIO has been the topic of several research analyst reports. Scotiabank cut their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research report on Monday, July 28th. Wall Street Zen cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 19th. Finally, Bank of America cut their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.